VERASTEM INC (VSTM)

Verastem is Now Oversold (VSTM)

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

VSTM Stock Earnings: Verastem Misses EPS for Q4 2023

VSTM stock results show that Verastem missed analyst estimates for earnings per share the fourth quarter of 2023.

VSTM Stock Earnings: Verastem Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Verastem (NASDAQ:VSTM) just reported results for the fourth quarter of 2023.Ver...

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024

Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio.

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem gets FDA fast track status for lung cancer drug combo (NASDAQ:VSTM)

Verastem (VSTM) avutometinib in combination with Amgen's Lumakras has received FDA fast track status in the treatment of a certain type of lung cancer. Read more here.

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Verastem starts Phase 3 study for ovarian cancer drug combination (NASDAQ:VSTM)

Verastem Oncology (VSTM) has initiated a confirmatory Phase 3 study of avutometinib and defactinib in the treatment of recurrent low-grade serous ovarian cancer. Read more here.

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

Verastem files $300M mixed securities shelf (NASDAQ:VSTM)

Verastem (VSTM) files a prospectus for a $300M mixed shelf offering, though it does not represent a sale of securities.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

Verastem Oncology appoints Dan Calkins as CFO (NASDAQ:VSTM)

Verastem Oncology strengthens leadership team with key appointments including new CFO, chief commercial officer, and head of regulatory affairs.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Verastem Oncology to Participate in Upcoming Investor Conferences

3 Penny Stocks That Can Triple Your Money in the Next 12 Months

Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.